Status:
WITHDRAWN
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Conditions:
Lung Cancer
Eligibility:
All Genders
18-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopp...
Detailed Description
OBJECTIVES: Primary * To determine the tumor response rate in patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib mala...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
- Stage IV disease
- At least 1 measurable lesion as defined by modified RECIST criteria
- No symptomatic or untreated brain metastases
- Prior brain metastases allowed provided the CNS disease has been treated and is considered stable and the patient has recovered from the acute toxic effects of the treatment prior to study entry
- PATIENT CHARACTERISTICS:
- Inclusion criteria:
- ECOG performance status 0-1
- WBC ≥ 3.0 x 10\^9/L
- ANC ≥ 1.5 x 10\^9/L
- Platelet count ≥ 100 x 10\^9/L
- Bilirubin ≤ 1.5 mg/dL
- AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if liver has tumor involvement)
- Creatinine ≤ 1.5 mg/dL
- LVEF ≥ 40% by MUGA
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- Exclusion criteria:
- Congestive heart failure, myocardial infarction, or coronary artery bypass graft within the past 12 months
- Ongoing severe or unstable angina
- Unstable arrhythmia requiring medication
- Sensory neuropathy ≥ grade 2 (according to NCI CTCAE v3.0)
- Known hypersensitivity to any of the agents used in this study
- Serious medical or psychiatric illness that, in the opinion of the enrolling investigator, is likely to interfere with study participation
- PRIOR CONCURRENT THERAPY:
- No prior systemic therapy for NSCLC
- More than 4 weeks since prior major surgery
- More than 7 days since prior and no concurrent potent CYP3A4 inhibitors, including any of the following:
- Ketoconazole
- Itraconazole
- Clarithromycin
- Erythromycin
- Diltiazem
- Verapamil
- Delavirdine
- Indinavir
- Saquinavir
- Ritonavir
- Atazanavir
- Nelfinavir
- More than 12 days since prior and no concurrent potent CYP3A4 inducers, including any of the following:
- Rifampin
- Rifabutin
- Carbamazepine
- Phenobarbital
- Phenytoin
- St. John's wort
- Efavirenz
- Tipranavir
- No concurrent treatment with a drug having proarrhythmic potential, including any of the following:
- Terfenadine
- Quinidine
- Procainamide
- Disopyramide
- Sotalol
- Probucol
- Bepridil
- Haloperidol
- Risperidone
- Indapamide
- Flecainide
- No other concurrent investigational agents
Exclusion
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00748163
Start Date
August 1 2008
End Date
August 1 2008
Last Update
August 8 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.